Genentech Inc (NYSE:DNA) to Release Q1 2008 Earnings April 10

Genentech, Inc (NYSE:DNA) will release the first quarter earnings for 2008 on Thursday, April 10.

A biotechnology company, Genentech is involved in the development, manufacture and commercialization of pharmaceutical products for the treatment of unmet medical needs.  The company commercializes multiple biotechnology products and receives royalties from companies that are licensed to market products based on the Company’s technology.

The company commercializes its products, such as Avastin, Rituxan, Herceptin, Lucentis, Xlair, Tarcev, Nutropin, Activase, TNKase, Cathflo Activase, Pulmozyme and Raptiva, in the United States.  Trasuzumab, rituximab, Bevacizumab, Dornase alfa, recombinant, Alteplase and Tenecteplase, Somatropin, Daclizumab, Ranibizumab, etanercept, Adalimumab and Infliximab are licensed products of Genentech, Inc.

View more Earnings related events or post your own on Finditt Events.